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Introduction
Barrett’s esophagus (BE) is a premalignant condition character-
ized by the replacement of the native esophageal squamous
epithelium by columnar epithelial with intestinal metaplasia
(IM) [1, 2]. BE predisposes to esophageal adenocarcinoma, an
aggressive cancer with an overall 5-year survival of only 17%
[3]. Radiofrequency ablation (RFA) has been established as a
safe, effective and durable treatment for flat, dysplastic BE,
[4–7]. RFA is delivered using the BARRX system, which compri-
ses a circumferential ablation device (BARRX 360) and focal ab-
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ABSTRACT
Background and study aims The standard radiofrequen-
cy ablation (RFA) protocol for Barrett’s esophagus (BE) en-
compasses an intermediary cleaning phase between two
ablation sessions. A simplified protocol omitting the clean-
ing phase is less labor-intensive but equally effective in
studies based on single ablation procedures. The aim of
this study was to compare efficacy and safety of the stand-
ard and simplified RFA protocols for the whole treatment
pathway for BE, including both circumferential and focal
devices.
Patients and methods We performed a retrospective a-
nalysis of prospectively collected data on patients receiving
RFA between January 2007 and August 2017 at two institu-
tions. Outcomes assessed were: 1) complete remission of
dysplasia (CR-D) and intestinal metaplasia (CR-IM) at 18
months; and 2) rate of esophageal strictures.
Results One hundred forty-five patients were included of
whom 73 patients received the standard and 72 patients re-
ceived the simplified protocol. CR-D was achieved in 94.5%
and 95.8% of patients receiving the standard and simplified
protocol, respectively (P=0.71). CR-IM was achieved in
84.9% and 77.8% of patients treated with the standard
and simplified protocol, respectively (P=0.27). Strictures
were significantly more common among patients who re-
ceived the simplified protocol (12.5%) compared to the
standard protocol (1.4%; P=0.008). The median number of
esophageal dilations was one.
Conclusion The simplified RFA protocol is as effective as
the standard protocol in eradicating BE but carries a higher
risk of strictures. This needs to be taken into account, parti-
cularly in patients with higher pretreatment risk of stric-
tures, such as those with esophageal narrowing from pre-
vious endoscopic mucosal resection (EMR).
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lation devices (BARRX 60, BARRX 90, BARRX Ultra or through-
the-scope device).
RFA protocol varies between institutions. The most com-
monly applied protocol incorporates a cleaning phase, whereby
debris from the ablated mucosa (one ablation at 12 J/cm2 for
circumferential RFA or two ablations at 15 J/cm2 for focal RFA)
is removed with cleaning devices, followed by a second round
of ablation with an energy setting identical to the first [8–11].
This regimen is referred to as the “standard protocol.” Although
effective, this regimen is tedious and time-consuming and re-
quires multiple intubations.
To reduce procedural time and increase tolerability of RFA,
van Vilsteren et al performed two randomized studies to evalu-
ate the efficacy of a “simplified protocol” which omits the
cleaning phase. In the first study, circumferential ablations
with standard (1 ×12 J/cm2-clean-1 ×12 J/cm2) versus simplified
(2 ×12 J/cm2) protocol without cleaning were found to be
equally effective based on subjective assessment of the percen-
tage of BE regression at follow-up [12]. In the second study,
investigators randomized single islands of Barrett’s mucosa to
either standard (2×15 J/cm2-clean-2×15 J/cm2) or simplified
(3 ×15 J/cm2-no clean) focal protocols and found no significant
difference between the two [13].
Following this evidence, many centers have adopted the
simplified protocol as it is easier and better tolerated by pa-
tients, however, the randomized studies only referred to effica-
cy and safety of individual treatments and not the overall treat-
ment pathway. A retrospective study of 83 patients showed
that multiple treatments over time with the simplified protocol
(3 ×15 J/cm2-no clean) achieved CR-D and CR-IM in 94% and
87 % of patients, respectively, but were complicated by stric-
tures in 11% of patients, who required a median of two dilation
sessions [14]. However, there remain concerns that consecutive
ablations may cause deeper damage to the esophageal mucosa,
possibly due to build-up of radiofrequency energy, which may
cause strictures. The dosimetry of 3×15 J/cm2 for the simplified
protocol was thought to be too aggressive and following a con-
sensus meeting in Amsterdam, a lower dose of 3 ×12 J/cm2 was
suggested. Therefore, most European centers have now adop-
ted the lower 3×12 J/cm2 dose for focal ablations. Currently
there is still no universally defined regimen for RFA for dysplas-
tic BE and data are lacking on efficacy and safety of the two pro-
tocols when they are assessed over the course of the entire RFA
treatment pathway. The aim of this study was to investigate ef-
ficacy and safety of the standard and simplified protocols for
treatment of BE including both circumferential and focal treat-
ments. We hypothesize that the simplified protocol will be as
effective as the standard protocol in achieving CR-D and CR-IM
but may carry a higher risk of strictures.
Patients and methods
We performed a retrospective analysis of prospectively collec-
ted data among patients who received RFA treatment for dys-
plastic BE between July 2007 to August 2017 at two UK tertiary
referral centers.
Inclusion criteria
Patients were eligible if they had flat BE with low-grade dyspla-
sia (LGD) or high-grade dysplasia (HGD) and residual BE post-
endoscopic mucosal resection (EMR) for low-risk BE-related
early cancer. BE was defined as presence of endoscopically visi-
ble columnar epithelial with biopsy confirming IM. For LGD, RFA
was performed once LGD was confirmed by two gastrointesti-
nal pathologists on two separate endoscopies. For flat HGD,
RFA was performed after histological confirmation from a sin-
gle endoscopy by two gastrointestinal pathologists. Low-risk
intramucosal carcinoma (IMC) was defined as well-differenti-
ated IMC (T1b sm1, within 500 um of the submucosa) without
lymphovascular invasion. Dysplasia was classified according to
the Vienna Classification [15]. Patients were categorized ac-
cording to the highest grade of dysplasia detected during their
endoscopic management. Patients who had prior EMR for nod-
ular BE were eligible for inclusion if they underwent subsequent
RFA.
Endoscopic procedures
Patients were scoped with GIF-FQ260Z, GIF-H290Z or GIF-
HQ290 endoscopes (Olympus, Tokyo). BE was graded accord-
ing to the Prague classification [16]. Random quadrantic biop-
sies were taken with adherence to the Seattle protocol [17].
Visible lesions seen during endoscopy were classified according
to the Paris classification [18]. Superficial lesions (type 0) were
treated with EMR for full histopathological staging. RFA was
then performed on the residual flat BE at least 6 weeks post-
EMR.
Radiofrequency ablation protocol
RFA was performed using the BARRX ablation devices (Medtro-
nic; Sunnyvale, California, United States). RFA was repeated at
roughly 3-month intervals. Circumferential ablation was per-
formed with an appropriate-size balloon selected after estima-
tion of esophageal diameter using a sizing balloon. Sizing and
treatment balloons were introduced blindly over a guidewire.
In patients with previous EMR, a smaller balloon was used as
per manufacturer’s recommendation.
Circumferential ablation with the standard protocol was per-
formed for each segment of the BE starting from the proximal
end with one ablation at 12 J/cm2, followed by cleaning of
mucosal slough with esophageal cap, patient extubation,
cleaning of ablation device with wet gauze, and finally a second
ablation at 12 J/cm2 (1×12 J/cm2-clean-1×12 J/cm2). Focal abla-
tion using the standard protocol was performed with two abla-
tions at 15 J/cm2, until coverage of the whole segment, fol-
lowed by cleaning of the mucosal slough with the focal device,
patient extubation, cleaning of the RFA device with wet gauze
and finally further treatment with two ablations at 15 J/cm2
per BE area (2 ×15 J/cm2-clean-2 ×15 J/cm2).
Circumferential ablation using the simplified protocol was
performed with two consecutive ablations at 12 J/cm2 without
cleaning (2×12 J/cm2-no clean) for each segment of the BE until
coverage of the whole BE area. Focal ablations were performed
with three consecutive ablations at 12 J/cm2 without cleaning
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(3 × 12 J/cm2-no clean). Focal ablations were performed using
the BARRX 60, BARRX 90, BARRX Ultra and BARRX Through-
the-scope (TTS) devices.
During follow-up, argon plasma coagulation was performed
at the discretion of the endoscopist to ablate small BE-islands.
Uptake of the simplified protocol varied between the institu-
tions with Cambridge adopting the simplified protocol from
November 2012, while Nottingham adopted the simplified pro-
tocol in January 2015. This change in practice led to some pa-
tients receiving a hybrid protocol with the standard protocol
during early treatments and the simplified protocol during later
visits. In this study, we only included patients who were treated
exclusively with either the standard or simplified protocols. We
also excluded patients who were treated with the more recent
BARRX Express device, which does not require sizing of the
esophageal lumen. These cases were excluded due to lack of
agreement among users about the optimal protocol to be
used, and because of the variation in practice even within the
same endoscopy unit.
Endoscopic follow-up
The interval between follow-up post-RFA was dependent on
baseline histology. Patients with LGD were seen at 6 months fol-
lowing complete pathological response and then at 12 months
and every 2 years thereafter. Patients with HGD or IMC were
seen at 3 months following complete pathological response,
and then at 6 months, and annually thereafter. At follow-up,
white-light and narrow-band imaging were used to inspect the
gastroesophageal junction (GEJ) to identify BE islands. Quad-
rantic biopsies were taken at the GEJ to detect IM or dysplasia
and every 2 cm within the neo-squamous epithelium to detect
buried IM. If IM was found at the GEJ at the first post-RFA follow-
up, circumferential ablation of the GEJ was performed with fo-
cal BARRX device. Focal IM in a single GEJ biopsy at the second
or subsequent endoscopic follow-up was not considered BE re-
currence and was not an indication for repeat RFA.
Outcome measures
Outcomes measure were: 1) complete remission of dysplasia
(CR-D) and complete remission of IM (CR-IM) at 18 months;
and 2) rate of esophageal strictures. CR-D was defined as eradi-
cation of dysplasia within 18 months, but with persistent co-
lumnar-lined epithelium with IM. CR-IM was defined as com-
plete eradication of both dysplasia and IM. Complete remission
of dysplasia or IM was defined as absence of dysplasia or IM on
two consecutive biopsies from the last RFA session. We also as-
sessed the rate of strictures post-RFA. Stricture was defined as
symptomatic esophageal narrowing requiring dilation to im-
prove symptoms or to allow endoscope passage. Asymptomat-
ic narrowing passed by the endoscope was not considered stric-
tures. Patients were only considered to have an RFA-related
stricture if the stricture developed after commencing RFA. Pa-
tients who had previous stricture secondary to prior-EMR were
not considered to have a stricture, unless the stricture recurred
after RFA. Esophageal dilation was performed with a through-
the-scope device with the aim of providing symptomatic relief
rather than achieving a specific size of the esophagus. The size
of the dilatation balloon was selected based on the estimated
diameter of the esophagus. If required, open biopsy forceps
were used to size the stricture. We also assessed whether age,
gender, maximum length of BE, prior-EMR, extent of prior-EMR,
baseline histology, type of RFA protocol, and different ablation
devices were predictors of stricture formation. For patients who
received prior-EMR, the number of EMR specimens performed
during a single session was recorded as a continuous variable
and acted as a surrogate for the extent of prior-EMR.
Statistical analyses
Normality testing was performed using the Shapiro-Wilk test.
For descriptive statistics, mean (± standard deviation, SD) was
used for parametric variables and median (interquartile range,
IQR) was used for non-parametric variables. Independent stu-
dent’s t-test and Mann-Whitney test were used to compare
means between groups. Rates of CR-D, CR-IM and strictures be-
tween groups were compared using Chi-squared test. Binary lo-
gistic regression was used to assess for predictors of stricture
formation. P<0.05 was considered statistically significant. Sta-
tistical analysis was performed using SPSS (version 24; Armonk,
New York, United States, IBM Corp).
Results
Patient characteristics
In total, 311 patients underwent RFA between July 2007 and
August 2017.Of them, 166 patients were excluded due to on-
going RFA treatment (n=102), combination protocol (n =20),
loss to follow-up (n =18), RFA for non-Barrett’s disease (n =
11), BARRX Express device used (n=8), treatment interrupted
because of other co-morbidities (n =6) and patient refusal of
further treatment (n =1) (▶Fig. 1). A total of 145 patients (97
from Cambridge and 48 from Nottingham) completed the 18-
month RFA protocol and were included in our analysis. Of the
145 patients, 73 were exclusively treated with the standard
protocol, while 72 patients received the simplified protocol.
Barrett’s esophagus with LGD, HGD or IMC (n = 311)
Completed RFA treatment (n = 145)
Standard protocol 
(n = 73)
Simplified protocol
(n = 72)
Patient excluded (n = 166)
▪Ongoing treatment: 102
▪Combination protocol: 20
▪Loss to follow-up: 18
▪Non-Barrett’s disease: 11 
▪BARRXTM Express: 8
▶ Fig. 1 Comparative analysis of radiofrequency ablation (RFA) for
standard versus simplified protocol: study flowchart.
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Mean age was 66.6 years and males (86.2%) were the predomi-
nant gender. The median length of BE was 4 cm (IQR 4.0 cm)
and 61.4% of patients received prior-EMR. For patients who re-
ceived prior-EMR, the median number of EMR specimens re-
sected (a surrogate for extent of prior-EMR) was 3 (IQR 2). Five
cases had missing data on the extent of EMR (▶Table1).
When stratified by protocol type (standard vs simplified),
there was no significant difference between the groups in
terms of age, gender ratio, BE maximum length, rate of rescue
EMR and number of RFA sessions within 18 months. There was
no significant difference between the groups in terms of grade
of dysplasia, however, the number of LGD cases in the standard
protocol group was smaller, in keeping with the fact that RFA
for LGD was only recently approved by the British Society of
Gastroenterology [19, 20].
RFA outcomes at protocol endpoint
At protocol endpoint of 18 months, 95.2% and 81.4% of pa-
tients achieved CR-D and CR-IM, respectively, with a median of
two ablations. When stratified to different RFA protocols, there
was no significant difference in CR-D outcomes between the
standard (94.5%) and simplified (95.8%) protocol (P=0.71). Si-
milarly, there was no significant difference in CR-IM between
the standard (84.9%) and simplified (77.8%) protocol (P=
0.27). Twelve patients (8.3%) developed visible nodular lesions
during follow-up and required rescue EMR. Among them, only
two patients had their BE upstaged. One patient had RFA per-
formed for LGD but required rescue EMR 6 months later, which
showed HGD. This patient achieved CR-IM at the end of the
protocol. Another patient with baseline HGD required rescue
EMR, which showed upstaging of disease to IMC. This patient
did not achieve CR-D at the protocol endpoint. The remaining
10 patients who received rescue EMR did not have their disease
upstaged (▶Table2).
Complications from RFA
Ten patients (6.9%, 95% CI 2.7–11.1) developed esophageal
strictures. One patient in the standard protocol group devel-
oped a stricture (1.4%, 95% CI 0–4.1) compared to nine pa-
tients (12.5%, 95% CI 4.7–20.3) in the simplified protocol
group (P=0.008) (▶Table 3). A median of one dilation session
was required to treat the stenosis (range 1–7). Two patients re-
quired more than one dilation, one of whom required two dila-
tion sessions and the other required seven dilation sessions.
Among the 12 patients who required rescue-EMR, only one pa-
tient developed a stricture, which occurred after the first RFA
(BARRX 360) and prior to the rescue EMR.
We also looked for clinical predictors of stricture following
RFA. We assessed age, gender, maximum length of BE, prior-
EMR, extent of prior-EMR, baseline histology and type of RFA
protocol as predictors of stricture formation post-RFA. Logistic
regression showed that protocol type was the only significant
predictor of stricture. The simplified protocol was associated
with 11 times greater odds of developing strictures compared
to the standard protocol (OR: 11.0, 95% CI 1.27–83.45, P=
0.029). Extent of prior EMR had no association with risk of de-
veloping strictures (OR 1.09, 95% CI 0.76–1.57, P=0.63).
With regard to the type of device used, we considered a total
of 371 ablations performed. Type of ablation device (BARRX
360, BARRX 90, BARRX-TTS, BARRX Ultra and BARRX 60) also
was not associated with risk of stricture (P=0.78) (▶Table 4).
We observed serious adverse events (SAE) in two patients
treated with the standard protocol. One patient developed
symptomatic atrial fibrillation within 36 hours after two abla-
▶ Table 1 Patient baseline characteristics stratified by different RFA protocols.
Variable Standard protocol Simplified protocol All patients P value
Number of patients 73 72 145 –
Age, mean (SD) 66.3 (9.0) 67.0 (9.7) 66.6 (9.3) 0.661
Gender (% males) 86.3 86.2 86.2 0.972
BE length, M value (median, IQR) 5.0 (5.0) 4.0 (4.0) 4.0 (4.0) 0.353
Prior EMR, n (%) 47 (64.4) 42 (58.3) 89 (61.4) 0.452
Extent of prior EMR4 (median, IQR) 2 (2) 3 (3) 3 (2) 0.123
Number of RFA (median IQR) 3 (1) 2 (1) 2 (1) 0.173
Grade of dysplasia, n (%) – – – 0.0822
▪ LGD 7 (9.6) 13 (18.1) 20 (13.8)
▪ HGD 27 (37.0) 33 (45.8) 60 (41.4)
▪ IMC 39 (53.4) 26 (36.1) 65 (44.8)
SD, standard deviation; IQR, interquartile range; lGD, low-grade dysplasia; HGD, high-grade dysplasia; IMC, intramucosal cancer; EMR; endoscopic mucosal resection
1 Studentʼs t test
2 Chi-square test
3 Mann-Whitney test
4 The extent of prior EMR was recorded as the number of EMR resections performed during a single session. The number of EMR resections was then used as a sur-
rogate for the extent of prior EMR.
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tions (one with circumferential and one with focal device) and
required pharmacological cardioversion. Another patient was
admitted within 48 hours after RFA with severe chest pain and
dysphagia, which was not related to esophageal stricture and
was managed conservatively with analgesia and intravenous
fluids. We also observed one SAE in a patient treated with the
simplified protocol who developed melena 48 hours after RFA.
Gastroscopy showed no evidence of active bleeding and he was
discharged after observation for 24 hours.
Discussion
RFA for BE has been widely available for over a decade, however,
there is geographical variation in the protocol used in clinical
practice and there remains uncertainty about the optimal ener-
gy dosimetry. Early studies of focal RFA used a regimen with a
single ablation, followed by cleaning of the ablation zone and
subsequent application of a single ablation [10, 11]. However,
due to lack of efficacy, the number of ablations were doubled
(2 ×12 J/cm2-cleaning-2×12 J/cm2) resulting in a higher rate of
BE eradication [11]. However, subsequent RFA studies on HGD
and EAC, which assessed higher-energy dosimetry, showed that
a (2×15 J/cm2-cleaning-2 ×15 J/cm2) resulted in better efficacy
without compromising the complication rate [10]. This higher
dosimetry was then incorporated into European practices, how-
ever, the 2 x12 J/cm2-cleaning-2 ×12 J/cm2 was still favored in
US-based studies for focal ablation [14].
It was then hypothesized that the intermediary cleaning
phase using the esophageal cap could inherently lead to muco-
sal edema, decreasing efficacy of the second cycle of ablations.
In two randomized trials based on single RFA procedures, Van
Vilsteren et al showed that the simplified protocol without
cleaning for both circumferential or focal RFA was equally effec-
tive as the standard protocol [12, 13]. Although omitting the
cleaning phase did not reduce RFA efficacy, it allowed for a
shorter procedure time. However, these studies only compared
ablation outcomes of a single treatment session, hence the
overall safety of the entire treatment pathway could not be as-
sessed.
▶ Table 2 Characteristics of patients who required rescue-EMR.
Case RFA protocol Baseline BE histology Rescue EMR histology Development of stricture at end of study
1 Standard HGD HGD No
2 Standard IMC Squamous No
3 Standard LGD HGD No
4 Standard IMC LGD Yes1
5 Standard IMC HGD No
6 Standard IMC LGD No
7 Standard LGD LGD No
8 Simplified HGD NDBE No
9 Simplified HGD IMC No
10 Simplified IMC IMC No
11 Simplified HGD HGD No
12 Simplified HGD NDBE No
EMR, endoscopic mucosal resection; RFA, radiofrequency ablation; BE, Barrett’s esophagus; NDBE, non-dysplastic Barrett’s esophagus; LGD, low-grade dysplasia;
HGD, high-grade dysplasia; IMC, intramucosal carcinoma
1 Stricture developed after RFA and prior to receiving rescue EMR
▶ Table 3 Comparative outcomes of RFA with standard versus simplified protocol.
Variable Standard protocol (n=73) Simplified protocol (n =72) All patients (n =145) P value
CR-D, % (95% CI) 94.5 (89.2–99.9) 95.8 (91.1 –100) 95.2 (91.6 –98.7) 0.711
CR-IM, % (95% CI) 84.9 (76.5–93.3) 77.8 (67.9 –87.6) 81.4 (75.0 –87.8) 0.271
Rescue EMR, % (95% CI) 9.6 (2.7–16.5) 6.9 (0.9–13.0) 8.3 (3.7–12.8) 0.561
Strictures, % (95% CI) 1.4 (0–4.1) 12.5 (4.7–20.3) 6.9 (2.7–11.1) 0.0081
CR-D, complete remission of dysplasia; CR-IM, complete remission of intestinal metaplasia; CI, confidence interval; EMR, endoscopic mucosal resection
1 Chi-square test
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Kunzli et al then compared the efficacy of the simplified pro-
tocol using focal ablation device only (BARRX 90) for the whole
treatment pathway. Once again, the simplified protocol was ef-
fective in BE eradication compared to historical literature, but
induced esophageal strictures in 11% patients. Although the
median number of dilations required was two, three patients
required at least eight endoscopic dilations [14]. More recently,
Pouw et al conducted a randomized non-inferiority trial
comparing the efficacy of the simplified (3×12 J/cm2) and
standard (2 ×15 J/cm2-cleaning-2 ×15 J/cm2) regimen using
focal RFA for dysplastic BE with a pre-specified non-inferiority
margin of –15% and showed that the simplified protocol was
non-inferior to the standard protocol in achieving BE surface
regression after two ablation sessions [21]. Esophageal steno-
sis, which was one of the secondary outcomes in this study,
showed no difference between the simplified and standard
protocol (9% vs 11%, P=1) [21]. The latter two studies only as-
sessed focal ablations using the BARRX 90 for ablation of BE is-
lands and tongues. Eligibility criteria allowed for patients with
preceding circumferential ablation using BARRX 360, however,
it was not specified whether patients who receive circumferen-
tial ablation were treated with the standard of simplified proto-
col, or combination of both [14]. In our study, we included pa-
tients who were exclusively treated with either the simplified or
standard protocol for the whole treatment pathway of BE, in-
cluding both circumferential and focal ablation as clinically in-
dicated. Our results showed that outcomes of CR-D and CR-IM
were similar with the standard and simplified protocols.
However, we found a higher number of strictures in patients
treated with the simplified protocol. The rate of strictures was
significantly higher in the simplified protocol (12.5%) compar-
ed to the standard protocol (1.4%). This could be secondary to
the “stacking” of energy with consecutive ablations which pe-
netrate deeper into the esophageal wall, leading to more exten-
sive damage and stricture development. Although the random-
ized trial by Pouw et al showed no significant difference be-
tween the rate of esophageal strictures, that study was pow-
ered to detect a difference between BE surface regression, and
not to detect a difference between the rate of strictures. Fur-
ther, this study also did not include patients undergoing cir-
cumferential ablation [21].
The higher stricture rate for the simplified protocol needs to
be considered in cases that have a higher pretreatment prob-
ability of stricture, such as those with preexisting stricture
from previous EMR who could have already been treated with
dilatation. For these cases, the standard ablation protocol could
be used. The ablation device used in our study was the older-
generation BARRX 360 circumferential device with separate siz-
ing balloon, which is no longer commercially available and has
been replaced by the BARRX 360 Express catheter. The findings
from our study have potential implications for the new BARRX
360 Express device, which is longer and more compliant to the
esophagus than the BARRX 360 circumferential device and has
been shown to correlate in early clinical experience to a high
rate of strictures [22, 23]. Our data would suggest caution in se-
lecting the simplified protocol without cleaning phase when
using the BARRX 360 Express device. None of the patients in-
cluded in our study were treated with the BARRX 360 express
catheter. A randomized trial is currently ongoing to assess the
comparative efficacy and safety of standard and simplified pro-
tocol for BARRX 360 express [22].
In our current study, we selected a more liberal RFA protocol
duration of 18 months compared to 12 months for the UK reg-
istry, and in other prospective studies, as we felt that this more
accurately reflects the high demands and prolonged waiting list
for endoscopy seen in large UK tertiary hospitals [4, 24]. Al-
though this could lead to overestimation of CR-D and CR-IM, in
this study, the mean number of ablations over 18 months (2.6)
was comparable to the mean number of ablations in the UK
Registry over 12 months (2.5) [24].
Our study does have some limitations. First, it was not pow-
ered to detect a difference in stricture rate between the
groups. Second, we only assessed short-term outcomes of
RFA. Although we applied a rigorous protocol with two conse-
cutive biopsies to confirm CR-D or CR-IM, overall follow-up was
relatively short, therefore, our data are insufficient to provide
information on the durability of RFA comparing these two pro-
tocols. However, the long-term durability of RFA in one of the
two centers has been reported elsewhere [7]. Third, RFA was
performed in tertiary institutions with high-volume caseload
and experienced endoscopists, therefore, the results of this
study may not necessarily reflect the practice in small-volume
centers. Finally, the observed rate of strictures within the
standard protocol group (1.4%) was lower than that observed
in the previous prospective and registry studies. While we are
unable to explain this low stricture rate, we cannot exclude
that it may have had an impact on the difference observed be-
tween the two groups.
Conclusion
In conclusion, we showed that the simplified RFA protocol for
the whole treatment pathway, including both circumferential
and focal ablations, is just as effective as the standard protocol.
The added benefit of fewer introductions of the device, shorter
procedural time, and likely less discomfort for patients makes it
favorable. However, the higher rate of strictures needs to be
considered when making decisions on an individual basis, espe-
▶ Table 4 Comparative outcomes of RFA for different devices.
Ablation devices Number of
strictures
P value
Total BARRX ablations (n =371) 10 0.781
▪ BARRX 360 (n =75) 3
▪ BARRX 90 (n =239) 5
▪ BARRX TTS (n =13) 0
▪ BARRX Ultra (n = 23) 1
▪ BARRX 60 (n =21) 1
TTS, through-the-scope
1 Chi-squared test
E194 Tan Wei Keith et al. Standard versus simplified… Endoscopy International Open 2020; 08: E189–E195
Original article
cially in patients with higher pretreatment probability of stric-
ture, such as those with esophageal stenosis from previous
EMR.
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